IAG’s Team Publishes a Book Chapter ‘Radiomics as Applied in Precision Medicine’ in the Textbook ‘Clinical Nuclear Medicine, 3red ed. Springer’ by Springer Nature Switzerland AG.
IAG, imaging expert company helps to accelerate novel drug development by using the right analytical tools and modern trial infrastructure.
This includes bringing AI, Machine Learning and smart image analysis methods to ensure the speed and cost-effectiveness, while delivering true insights about the mechanism of action and patients’ response.
Our expert team has been deploying advanced imaging and associated analytics in clinical trials to assess new drug efficacy and patient response.
Radiomics is one of the AI driven methodologies.
This is a quantitative image analysis technique that leverages machine learning to extract and classify features from imaging studies to create signatures that serve as imaging biomarkers of the underlying disease process and its clinical course.
The field of radiomics is expanding, and it has numerous applications in immunologic and oncologic disease.
Today, clinical trials are starting to include radiomics as a scientific/exploratory endpoint. This allows to study disease behavior, clinical outcomes and therapy response.
Book Title: Clinical Nuclear Medicine, Springer Nature Switzerland AG
Chapter Title: ‘Radiomics as Applied in Precision Medicine’ pp. 193 – 207
Authors: Faiq Shaikh, Benjamin Franc, Francisca Mulero
Read full publication here
Faiq Shaikh, M.D. Dr. Faiq Shaikh is IAG’s Head of Research & Enterprise. His background is in medical imaging and informatics. He is a physician with deep expertise in the use of molecular imaging, novel tracers and radiomics in clinical studies. Faiq is closely working with the world-class academic centres, biotechnology and pharmaceutical companies bringing predictive analytics and AI-based outcomes measures to drug development and clinical decision making.
is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development.